EGFR inhibits TNF-α-mediated pathway by phosphorylating TNFR1 at tyrosine 360 and 401.
Young Woo NamJune-Ha ShinSeongmi KimChi Hyun HwangChoong-Sil LeeGyuho HwangHwa-Ryeon KimJae-Seok RoeJaekyoung SonPublished in: Cell death and differentiation (2024)
Tumour necrosis factor receptor 1 (TNFR1) induces the nuclear factor kappa-B (NF-κB) signalling pathway and regulated cell death processes when TNF-α ligates with it. Although mechanisms regulating the downstream pathways of TNFR1 have been elucidated, the direct regulation of TNFR1 itself is not well known. In this study, we showed that the kinase domain of the epidermal growth factor receptor (EGFR) regulates NF-κB signalling and TNF-α-induced cell death by directly phosphorylating TNFR1 at Tyr 360 and 401 in its death domain. In contrast, EGFR inhibition by EGFR inhibitors, such as erlotinib and gefitinib, prevented their interaction. Once TNFR1 is phosphorylated, its death domain induces the suppression of the NF-κB pathways, complex II-mediated apoptosis, or necrosome-dependent necroptosis. Physiologically, in mouse models, EGF treatment mitigates TNF-α-dependent necroptotic skin inflammation induced by treatment with IAP and caspase inhibitors. Our study revealed a novel role for EGFR in directly regulating TNF-α-related pathways.
Keyphrases
- epidermal growth factor receptor
- nuclear factor
- tyrosine kinase
- cell death
- advanced non small cell lung cancer
- rheumatoid arthritis
- small cell lung cancer
- toll like receptor
- oxidative stress
- signaling pathway
- lps induced
- pi k akt
- magnetic resonance
- mouse model
- transcription factor
- diabetic rats
- magnetic resonance imaging
- cell cycle arrest
- immune response
- replacement therapy
- combination therapy
- induced apoptosis
- growth factor
- contrast enhanced
- protein kinase